相关实验视频

Updated: May 1, 2026

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots

Published on: June 2, 2015

在3T3-L1脂肪细胞中抑制脂肪生成和脂质积累,无细胞毒性

Tien-Chou Soong^1,2, Kuan-Ting Lee³, Yi-Chiang Hsu⁴

¹Department of Weight Loss and Health Management Center, E-DA Dachang Hospital and I-Shou University, Kaohsiung 807, Taiwan.

|August 28, 2025

概括

甲酸E (CuE) 有效抑制3T3- L1脂肪细胞中的脂肪生成和脂质积累,而不会导致细胞死亡. 这种天然化合物可以作为一种安全的肥胖管理和功能性食物.

科学领域:

生物化学
细胞生物学
药理学

背景情况:

甲酸E (CuE) 是一种天然的甲酸植物化合物,具有已知的抗炎和抗癌特性.
它对脂质代谢和脂肪生成的影响尚不清楚.
这项研究研究了CuE的潜在抗肥胖和抗肥胖作用.

研究的目的:

在3T3-L1脂肪细胞中评估库库比他素E (CuE) 的抗脂肪生成和抗肥胖作用.
阐明CuE对脂肪生成作用的分子机制.
评估CuE在脂肪细胞中的安全性.

主要方法:

通过使用标准的脂肪生成尾酒来区分3T3- L1前脂肪细胞.
在分化过程中给予CuE,并通过Oil Red O染色测量脂质积累.
使用MTT测定,流细胞测量,西部抹杀和RT-PCR评估了细胞活力,细胞亡/死亡以及脂肪生成标志物的表达 (PPARγ,C/EBPα).

主要成果:

在不诱导亡或亡的情况下,CuE显著降低了脂质液滴的形成.
它降低了关键脂肪转录因子PPARγ和C/ EBPα的mRNA和蛋白质表达.
这些发现表明CuE对脂肪细胞分化具有非细胞毒性抑制作用.

结论:

通过抑制关键脂肪生成因子,甲酸E有效抑制3T3- L1脂肪细胞中的脂肪生成和脂质积累.
在有效度下,CuE表现出良好的安全性,没有细胞毒性作用.
是一种有前途的天然化合物,用于开发功能性食品或治疗肥胖症.

关键词:

3T3-L1细胞抗肥胖药物 (AOM)脂肪细胞的分化库库比他素E 肥胖问题

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...